(12) International Application Status Report

Received at International Bureau: 05 December 2017 (05.12.2017)

Information valid as of: 01 April 2019 (01.04.2019)

Report generated on: 22 April 2019 (22.04.2019)

(10) Publication number: (43) Publication date: (26) Publication language:
WO 2018/10055807 June 2018 (07.06.2018) English (EN)

(21) Application number: (22) Filing date: (25) Filing language:
PCT/IB2017/05758801 December 2017 (01.12.2017) English (EN)

(31) Priority number(s): (32) Priority date(s): (33) Priority status:
2016-234553 (JP)01 December 2016 (01.12.2016) Priority document received (in compliance with PCT Rule 17.1)
2017-107216 (JP)30 May 2017 (30.05.2017) Priority document received (in compliance with PCT Rule 17.1)
62/589,300 (US)21 November 2017 (21.11.2017) Priority document received (in compliance with PCT Rule 17.1)

(51) International Patent Classification:
C07H 21/00 (2006.01); C07H 21/02 (2006.01); A61K 31/7084 (2006.01); A61P 35/00 (2006.01)

(71) Applicant(s):
TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi Osaka, 541-0045 (JP) (for all designated states)

(72) Inventor(s):
YOSHIKAWA, Masato; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SAITOH, Morihisa; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
KATO, Taisuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
YOSHITOMI, Yayoi; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SEKI, Tomohiro; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
NAKAGAWA, Yasuo; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
TOMINARI, Yusuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SETO, Masaki; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SASAKI, Yusuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
OKANIWA, Masanori; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
ODA, Tsuneo; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SHIBUYA, Akito; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
HIDAKA, Kosuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
SHIOKAWA, Zenyu; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
MURATA, Shumpei; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
OKABE, Atsutoshi; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
NAKADA, Yoshihisa; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
MOCHIZUKI, Michiyo; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
FREEZE, Brian Scott; 67 Gates St, Unit 1 Boston, Massachusetts 02127 (US)
TAWARAISHI, Taisuke; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
WADA, Yasufumi; c/o Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa Kanagawa, 251-0012 (JP)
GREENSPAN, Paul D.; 8 Overlook Drive Acton, Massachusetts 01720 (US)


(54) Title (EN): CYCLIC DINUCLEOTIDES AS STING (STIMULATOR OF INTEFERON GENES) AGONISTS
(54) Title (FR): DINUCLÉOTIDE CYCLIQUE

(57) Abstract:
(EN): The present disclosure provides a compound having a STING (stimulator of interferon genes) agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases, such as cancer. The present disclosure relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.
(FR): La présente invention concerne un composé ayant une activité agoniste de STING, dont on s'attend à ce qu'il soit utile en tant qu'agent pour la prophylaxie ou le traitement de maladies associées à STING. La présente invention concerne un composé représenté par la formule (I), dans laquelle chaque symbole est tel que défini dans la spécification, ou un sel de celui-ci.

International search report:
Received at International Bureau: 06 June 2018 (06.06.2018) [EP]

International Report on Patentability (IPRP) Chapter II of the PCT:
Not available

(81) Designated States:
AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
European Patent Office (EPO) : AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
African Intellectual Property Organization (OAPI) : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG
African Regional Intellectual Property Organization (ARIPO) : BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW
Eurasian Patent Organization (EAPO) : AM, AZ, BY, KG, KZ, RU, TJ, TM